Business, energy, technology, markets and global industry news from Business News Today

oncology

PharmaDeviceNews oncology
Representative image of oncology research and blood cancer diagnostics. AbbVie’s DECNUPAZ approval highlights how CD123-targeted antibody-drug conjugates could reshape treatment options for blastic plasmacytoid dendritic cell neoplasm.
Pharma & Biotech

How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN

Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.

Read More
Pharma & Biotech

Can Brenus Pharma crack the cold-tumor problem in metastatic colorectal cancer?

Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.

Read More
Pharma & Biotech

Can United Immunity revive macrophage cell therapy after Carisma’s reset?

Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Representative image of an oncology researcher reviewing bladder cancer treatment data, as ImmunityBio’s ANKTIVA plus BCG analysis raises new questions about cost, response durability and bladder-sparing care in BCG-unresponsive NMIBC.
Pharma & Biotech

Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Read More
Representative image: An oncology specialist reviews treatment information with a breast cancer patient in a clinical setting, reflecting Gilead Sciences’ Trodelvy regulatory progress in first-line metastatic triple-negative breast cancer care.
Pharma & Biotech

Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning

Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Pharma & Biotech

Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

Read More
Pharma & Biotech

Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates

ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.

Read More
Representative image: Clinicians reviewing lung cancer imaging and genomic test results, reflecting Bayer’s HYRNUO FDA Priority Review and the growing role of precision oncology in HER2-mutated non-small cell lung cancer treatment.
Pharma & Biotech

Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing

Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.

Read More